Therapeutic approaches to secondary progressive multiple sclerosis.
Lublin
F D
FD
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY 10029, USA.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D017338:Cladribine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D020528:Multiple Sclerosis, Chronic Progressive / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D000068576:Interferon beta-1b; D017338:Cladribine; D016899:Interferon-beta; D016572:Cyclosporine; D008942:Mitoxantrone; D001379:Azathioprine; D008775:Methylprednisolone; D000068556:Interferon beta-1a; D008727:Methotrexate